Warning letter
Best Formulations: warning letter of Oct 29, 2002
FDA warning letter UCM145269 · Los Angeles District Office
Key facts
| Reference number | UCM145269 |
|---|---|
| Company | Best Formulations |
| Subject | CGMP for Finished Pharmaceuticals/CGMP in Manufacturing, Processing, Packing, or Holding/Adulterated |
| Issue date | Oct 29, 2002 |
| Posted date | Oct 29, 2002 |
| Issuing office | Los Angeles District Office |
| Product type | Drugs |
| CFR sections cited | 211.166, 211.110(a), 211.84(d), 211.165, 211.194, 211.67 |
| Country | 3 |
| Inspection city | City Of Industry |
| Inspection ZIP | 91748-1148 |
| Inspection start date | Jul 24, 2002 |
| Letter on fda.gov | web.archive.org |
At a glance
- 1–9 CFR sections cited
- OAI Linked inspection classification
- Yes Form FDA 483 issued
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About FDA warning letters
FDA warning letters notify a firm of significant regulatory violations found during an inspection or review and request prompt corrective action.
Source: U.S. Food and Drug Administration (FDA), Warning Letters · Source date: